Hefei’s anti-new crown special drug will be on the market soon

According to Hefei, on December 20, it was learned from Anhui Baker Pharmaceutical that the specific drug for the treatment of the new crown independently developed by the company has passed relevant clinical trials and professional review, and is currently awaiting approval for listing. It is understood that, as a small molecule inhibitor, monapiravir can interfere with the genetic code of the virus to make it go wrong, so as to achieve the purpose of clearing the virus, mainly for non-hospitalized patients with mild to moderate new coronary pneumonia at risk of exposure adult patients. | Related reading (published in Hefei)

Han Lei

After experiencing strict epidemic prevention and control, many people have wondered whether there is a special medicine? Then the new crown virus will not be so scary. Now Anhui Baker Pharmaceutical has developed a special drug, which finally brings good news to patients with new coronary pneumonia.

This winter, the virus infection is actively attacking on a large scale. In the words of Zhong Nanshan, Omicron, which has a fatality rate of about 0.1%, is about equal to ordinary seasonal flu. Because there are no symptoms of pneumonia, it is no longer suitable to be called new coronary pneumonia. The stage it has developed is actually the new crown. Respiratory tract infection, or simply called the new crown cold. Judging from the recovery of the infected people around us, the virus has weakened and is no longer scary.

Now the terrible infected people are mainly the elderly with underlying diseases. Baker’s special medicine is mainly aimed at adults with mild to moderate symptoms who are not hospitalized, but it is a good start to help this group of people. I believe that in the future, clinically effective drugs for severe patients will be developed, so that the new coronavirus can be completely cured.

This article is reproduced from: https://www.fortunechina.com/jingxuan/25457.htm
This site is only for collection, and the copyright belongs to the original author.